Acasti Pharma Inc. (ACST)

Acasti Pharma Balance Sheet

Financials in millions CAD. Fiscal year is April - March.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	23.01	27.88	30.34	50.94	14.24
Short-Term Investments	0	0.02	13.32	9.79	0
Cash & Cash Equivalents	23.01	27.89	43.66	60.73	14.24
Cash Growth	-17.52%	-36.12%	-28.11%	326.48%	-44.72%
Receivables	0.72	0.8	0.55	0.53	0.55
Other Current Assets	0.28	0.6	1.07	1.11	3.68
Total Current Assets	24.01	29.29	45.28	62.37	18.46
Property, Plant & Equipment	0.02	0.57	0.57	0.09	0.15
Goodwill and Intangibles	49.27	49.27	82.77	0	4.24
Total Long-Term Assets	49.29	49.83	83.34	0.09	4.39
Total Assets	73.3	79.12	128.62	62.46	22.85
Accounts Payable	1.68	3.34	3.16	1.49	7.32
Current Debt	0	0.08	0.1	0.09	0.08
Total Current Liabilities	1.68	3.41	3.26	1.58	7.4
Long-Term Debt	0	0.41	0.19	0	0.07
Other Long-Term Liabilities	9.87	7.35	16.9	5.22	2.39
Total Long-Term Liabilities	9.87	7.76	17.09	5.22	2.46
Total Liabilities	11.56	11.17	20.35	6.8	9.86
Total Debt	0	0.49	0.3	0.09	0.15
Debt Growth	-	64.41%	243.02%	-41.50%	-89.20%
Retained Earnings	-211.12	-198.27	-155.84	-146.02	-126.34
Comprehensive Income	-6.04	-6.04	-6.04	-6.33	-7.89
Shareholders' Equity	61.74	67.96	108.27	55.66	12.99
Net Cash / Debt	23.01	27.41	43.37	60.65	14.09
Net Cash / Debt Growth	-16.06%	-36.81%	-28.49%	330.32%	-42.24%
Net Cash Per Share	2.41	3.69	7.06	24.54	8.00
Working Capital	22.33	25.88	42.02	60.79	11.07
Book Value Per Share	6.48	9.14	17.63	22.52	7.37

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).